دورية أكاديمية
Melatonin in the Prophylaxis of SARS-CoV-2 Infection in Healthcare Workers (MeCOVID): A Randomised Clinical Trial.
| العنوان: | Melatonin in the Prophylaxis of SARS-CoV-2 Infection in Healthcare Workers (MeCOVID): A Randomised Clinical Trial. |
|---|---|
| المؤلفون: | García-García, Irene1,2 (AUTHOR) mariateresa.garcia@h12o.es, Seco-Meseguer, Enrique1 (AUTHOR) enriquesm.ucicec@gmail.com, Ruiz-Seco, Pilar3 (AUTHOR) mprseco@salud.madrid.org, Navarro-Jimenez, Gema3 (AUTHOR) gema.nvj@gmail.com, Martínez-Porqueras, Raúl4 (AUTHOR) raul.martinezporqueras@gmail.com, Espinosa-Díaz, María4 (AUTHOR) maclamana@gmail.com, Ortega-Albás, Juan José5 (AUTHOR) jjoralbas@gmail.com, Sagastagoitia, Iñigo6 (AUTHOR) sagastita@hotmail.com, García-Morales, María Teresa2,7 (AUTHOR), Jiménez-González, María1,2,8 (AUTHOR) jimenezglezmaria@gmail.com, Martínez de Soto, Lucía1,2 (AUTHOR) luciamds.ucicec@gmail.com, Bajo-Martínez, Ana Isabel9 (AUTHOR) aisabel.bajom@salud.madrid.org, del Palacio-Tamarit, María4 (AUTHOR) mariadelpalaciotamarit@yahoo.es, López-García, Raquel5 (AUTHOR) raquel_garnet@hotmail.com, Díaz-García, Lucía1 (AUTHOR) luciadiaz.ucicec@gmail.com, Queiruga-Parada, Javier1,8 (AUTHOR) javier.ucicec@gmail.com, Giesen, Christine10 (AUTHOR) christine.giesen@salud.madrid.org, Pérez-Villena, Ana11 (AUTHOR) aperezv@salud.madrid.org, de Castro-Martínez, Marta4 (AUTHOR) martadecastro84@gmail.com, González-García, Juan J.8,12,13 (AUTHOR) rodriguezrubio.miguel@gmail.com |
| المصدر: | Journal of Clinical Medicine. Feb2022, Vol. 11 Issue 4, pN.PAG-N.PAG. 1p. |
| مصطلحات موضوعية: | *MEDICAL personnel, *SARS-CoV-2, *MELATONIN, *CLINICAL trials, *PREVENTIVE medicine |
| مصطلحات جغرافية: | SPAIN |
| مستخلص: | We evaluated in this randomised, double-blind clinical trial the efficacy of melatonin as a prophylactic treatment for prevention of SARS-CoV-2 infection among healthcare workers at high risk of SARS-CoV-2 exposure. Healthcare workers fulfilling inclusion criteria were recruited in five hospitals in Spain and were randomised 1:1 to receive melatonin 2 mg administered orally for 12 weeks or placebo. The main outcome was the number of SARS-CoV-2 infections. A total of 344 volunteers were screened, and 314 were randomised: 151 to placebo and 163 to melatonin; 308 received the study treatment (148 placebo; 160 melatonin). We detected 13 SARS-CoV-2 infections, 2.6% in the placebo arm and 5.5% in the melatonin arm (p = 0.200). A total of 294 adverse events were detected in 127 participants (139 in placebo; 155 in melatonin). We found a statistically significant difference in the incidence of adverse events related to treatment: 43 in the placebo arm and 67 in the melatonin arm (p = 0.040), and in the number of participants suffering from somnolence related to treatment: 8.8% (n = 14) in the melatonin versus 1.4% (n = 2) in the placebo arm (p = 0.008). No severe adverse events related to treatment were reported. We cannot confirm our hypothesis that administration of melatonin prevents the development of SARS-CoV-2 infection in healthcare workers. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: | Academic Search Index |
Full Text Finder | تدمد: | 20770383 |
|---|---|
| DOI: | 10.3390/jcm11041139 |